adefovir dipivoxil + saquinavir + nucleoside reverse transcriptase inhibitor

This is a combination regimen consisting of **adefovir dipivoxil**, **saquinavir**, and a **nucleoside reverse transcriptase inhibitor** (NRTI), used in the context of multi-drug antiretroviral therapy for HIV infection. - **Adefovir dipivoxil** is an oral prodrug of adefovir, an acyclic nucleotide analog that inhibits HIV reverse transcriptase, blocking DNA replication and thereby stopping viral replication[3][5]. - **Saquinavir** is a protease inhibitor that blocks the HIV protease enzyme, preventing the maturation of infectious viral particles[2][4][8]. - **Nucleoside reverse transcriptase inhibitor** refers to agents like zidovudine (AZT), lamivudine (3TC), stavudine (d4T), which compete with natural nucleosides to terminate viral DNA synthesis by reverse transcriptase[3][5]. This combination was studied primarily as salvage therapy in HIV-infected individuals with prior treatment experience or resistance to first-line regimens. **Synergistic anti-HIV activity** has been reported between adefovir and both NRTIs and saquinavir, though pharmacokinetic interactions (notably with delavirdine and reduced saquinavir concentrations) limit use. Primary indication: treatment of HIV-1 infection in combination with other antiretroviral agents.

Other names

adefovir dipivoxil + saquinavir + nucleoside reverse transcriptase inhibitor